LNTH Stock Risk & Deep Value Analysis
Lantheus Holdings Inc
Healthcare • Drug Manufacturers - Specialty & Generic
DVR Score
out of 10
What You Need to Know About LNTH Stock
We analyzed Lantheus Holdings Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran LNTH through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
LNTH Risk Analysis & Red Flags
What Could Go Wrong
The biggest risk is that future pipeline products, particularly PNT2003, fail to achieve multi-billion dollar blockbuster status, especially considering the current deceleration and projected decline in core product (PYLARIFY) and overall revenue. If new launches in 2027 and beyond do not significantly outperform expectations, the stock could remain range-bound or decline.
Risk Matrix
Overall
Moderate
Financial
Low
Market
Medium
Competitive
Medium
Execution
Medium
Regulatory
Medium
Red Flags
- ⚠
FY2026 revenue guidance ($1.40-1.45B) indicates a projected decline from FY2025 revenue ($1.546B).
- ⚠
PYLARIFY, the flagship product, experienced a 9.7% year-over-year sales decline in Q4 2025.
- ⚠
Reliance on 2027 product launches for significant growth, creating a near-term growth vacuum.
Upcoming Risk Events
- 📅
Negative results or delays in PNT2003 clinical trials
- 📅
Worsening decline in PYLARIFY sales
- 📅
Increased competitive pressure or new market entrants in radiopharmaceuticals
- 📅
Any downward revision of FY2026/FY2027 financial guidance
When to Reconsider
- 🚪
Exit if FY2026 revenue guidance is revised downwards further.
- 🚪
Sell if PNT2003 clinical trial results disappoint or face significant delays beyond 2027.
- 🚪
Exit if overall operating margins compress significantly over two consecutive quarters.
Unlock LNTH Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Lantheus Holdings Inc (LNTH) Do?
Market Cap
$5.35B
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
808
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
Visit Lantheus Holdings Inc WebsiteInvestment Thesis
Lantheus Holdings is a profitable and innovative radiopharmaceutical company with a robust pipeline (e.g., PNT2003) poised to transition from diagnostics to high-growth oncology therapeutics. The investment thesis relies on successful clinical development and commercialization of these pipeline assets to offset near-term revenue deceleration and drive significant long-term growth and market expansion in specialized oncology treatment.
Is LNTH Stock Undervalued?
Unlock the full AI analysis for LNTH
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
LNTH Price Targets & Strategy
12-Month Target
$90.00
Bull Case
$98.00
Bear Case
$70.00
Valuation Basis
Based on 17.1x forward P/E applied to the midpoint of FY2026 EPS guidance ($5.12) which accounts for current market conditions and analyst sentiment.
Entry Strategy
Consider dollar-cost averaging on dips towards the $75-$80 support zone, especially if price nears its 50-day SMA ($78.08 based on recent momentum data) following any market corrections.
Exit Strategy
Take profit on partial positions above $95.00 (approaching analyst high PT); establish a stop-loss order below $70.00 (a significant break below recent YTD momentum and a level that would indicate fundamental deterioration).
Portfolio Allocation
1-2% for aggressive risk tolerance; not recommended for moderate or conservative portfolios aiming for 10x growth due to high uncertainty on this specific target.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is LNTH Financially Healthy?
Valuation
P/E Ratio
22.91
Forward P/E
23.00
EV/EBITDA
9.17
PEG Ratio
-3.69
Price/Book
6.60
Price/Sales
4.70
Profitability
Gross Margin
61.10%
Operating Margin
20.16%
Net Margin
15.15%
Return on Equity
20.58%
Revenue Growth
0.50%
EPS
$3.36
Balance Sheet
Current Ratio
2.70
Quick Ratio
2.51
Debt/Equity
0.52
Total Debt
$568.68M
Cash & Equivalents
$187.35M
Cash Flow
Operating Cash Flow
$305.26M
Free Cash Flow
-$13.06M
EBITDA
$356.54M
Other
Beta (Volatility)
-0.10
Does LNTH Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Eroding for established products like PYLARIFY due to slowing sales and potential for new competition, but potentially expanding with the successful development and commercialization of new therapeutic radioligands like PNT2003.
Moat Sources
2 Identified
The moat, primarily derived from intellectual property and regulatory hurdles in radiopharmaceuticals, offers durability for existing products. However, its longevity is constantly challenged by patent expirations, technological advancements by competitors, and the need for continuous pipeline innovation to replace declining legacy products.
Moat Erosion Risks
- •Patent expiry or successful challenges to existing IP.
- •Emergence of superior diagnostic or therapeutic alternatives from competitors.
- •Increased competition in the PSMA-targeted market or broader oncology segments.
LNTH Competitive Moat Analysis
Sign up to see competitive advantages
LNTH Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral. While recent stock momentum is positive, there's no strong indication of overwhelming retail investor enthusiasm or widespread 'meme stock' characteristics.
Institutional Sentiment
Positive-to-Neutral. Analyst consensus is 'Moderate Buy' with recent target increases by Truist Financial and an upgrade by Wall Street Zen. However, Vanguard's 13G/A filing indicated 0% ownership post-internal realignment.
Insider Activity (Form 4)
Daniel Niedzwiecki (executive) disposed 1,911 shares ($160K value) for tax withholding on April 17, 2026, retaining a substantial holding of 117,465 shares. No other significant insider buying/selling by CEO/CFO or other executives reported in the last 90 days.
Options Flow
Normal options activity; no specific data provided to indicate unusual institutional positioning (e.g., heavily skewed put/call ratio or large block trades).
Earnings Intelligence
Next Earnings
2026-05-06 (BMO)
Surprise Probability
Medium
Historical Earnings Pattern
Lantheus has historically demonstrated a tendency to beat EPS estimates, which often leads to short-term positive stock momentum, as seen with the Q4 2025 beat. However, investor reaction can be sensitive to forward guidance and flagship product sales trends.
Key Metrics to Watch
Competitive Position
Top Competitor
Not explicitly specified in research data, but common peers in radiopharmaceuticals include Telix Pharmaceuticals, Curium Pharma, and Blue Earth Diagnostics.
Market Share Trend
PYLARIFY's 9.7% YoY sales decline in Q4 2025 suggests either market saturation, increased competition, or a loss of market share in its segment, indicating a 'losing ground' trend for its core product, though the company aims for future growth through new launches.
Valuation vs Peers
LNTH trades at a trailing P/E (21.7x-24.53x) slightly above some general sector peers but below the broader US Medical Equipment average. Its forward P/E (16.1x) appears reasonable considering its profitability but may not justify significant multiple expansion given the projected revenue decline.
Competitive Advantages
- •Proprietary radiopharmaceutical portfolio and intellectual property for established products like PYLARIFY.
- •Established distribution network and prescriber base in diagnostic imaging.
- •Early-mover advantage and leadership in specific PSMA PET imaging segments.
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive LNTH Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (Expected May 6, 2026 BMO)
- •Updates on PNT2003 clinical trials (Phase 3 data expected in late 2026 or 2027)
Medium-Term (6-18 months)
- •Regulatory filings and potential approval for PNT2003 (2027+)
- •Launch of other pipeline products expected for 2027
- •Strategic partnerships to expand radiopharmaceutical reach
Long-Term (18+ months)
- •PNT2003 achieving blockbuster status and market leadership in PSMA-targeted radioligand therapy
- •Expansion into new therapeutic indications leveraging radiopharmaceutical platform
- •Sustainable leadership in next-generation oncology diagnostics and therapeutics
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for LNTH?
- ✓
Acceleration in pipeline development milestones for PNT2003 and other therapeutic candidates.
- ✓
Stabilization or renewed growth in PYLARIFY sales indicating sustained market demand or expanded use.
- ✓
Positive revisions to long-term revenue growth guidance (beyond FY2026).
Bull Case Analysis
See what could go right with Premium
Competing with LNTH
See how Lantheus Holdings Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Lantheus Holdings Inc LNTH | $5.4B | 1.0 | 22.9 | $406.8M | 15.2% | 0.5% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Lantheus Holdings Inc Makes Money
Lantheus Holdings Inc. is a radiopharmaceutical company that develops, manufactures, and commercializes innovative diagnostic and therapeutic products for medical imaging and targeted oncology treatments. They primarily generate revenue by selling specialized radiopharmaceuticals, such as PYLARIFY for prostate cancer imaging, to hospitals, imaging centers, and healthcare providers. Their business model focuses on leveraging proprietary compounds and regulatory expertise to address unmet medical needs in areas like cardiology, oncology, and neurology, with an increasing strategic pivot towards therapeutic agents.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Lantheus Holdings Inc (LNTH)?
As of April 23, 2026, Lantheus Holdings Inc has a DVR Score of 1.0 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Lantheus Holdings Inc?
Lantheus Holdings Inc's market capitalization is approximately $5.4B. The company operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry.
What ticker symbol does Lantheus Holdings Inc use?
LNTH is the ticker symbol for Lantheus Holdings Inc. The company trades on the NGM.
What is the risk level for LNTH stock?
Our analysis rates Lantheus Holdings Inc's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of LNTH?
Lantheus Holdings Inc currently has a price-to-earnings (P/E) ratio of 22.9. This is in line with broader market averages.
Is Lantheus Holdings Inc's revenue growing?
Lantheus Holdings Inc has reported revenue growth of 0.5%. The company is growing at a moderate pace.
Is LNTH stock profitable?
Lantheus Holdings Inc has a profit margin of 15.2%. The company is profitable but margins are modest.
How often is the LNTH DVR analysis updated?
Our AI-powered analysis of Lantheus Holdings Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 23, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for LNTH (Lantheus Holdings Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.